Our clinical pipeline is comprised of drug candidates and potential drug candidates that have arisen from our knowledge and expertise regarding the cytoskeleton. These clinical programs are focused on muscle contractility.
We are currently developing four small molecule compounds arising from our muscle contractility programs. Omecamtiv mecarbil, a novel cardiac muscle myosin activator, is currently in a Phase IIb clinical trials program for the potential treatment of heart failure. Tirasemtiv is our lead drug candidate from our skeletal muscle contractility program and is in Phase IIb clinical trials for the potential treatment of amyotrophic lateral sclerosis (ALS), also knows as Lou Gehrig's Disease. We have begun Phase I clinical trials with a second drug candidate, CK-2127107, from our skeletal muscle contractility program. We are also developing a smooth muscle myosin inhibitor which is currently in IND-enabling studies. We are continuing to conduct discovery, characterization and lead optimization activities for other compounds with the potential to modulate muscle contractility and other muscle functions.